Monday, September 24, 2018 7:07:53 AM
"At June 30, 2018, the Series A, Series B and Series C Warrants each have an exercise price of $0.0018 per share, which reflects adjustments pursuant to their terms. The Series A, Series B and Series C Warrants are subject to “full ratchet” and other customary anti-dilution protections."
https://www.sec.gov/Archives/edgar/data/931059/000149315218011538/form10-q.htm
Recent RNVA News
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration with ZenaDrone • InvestorsHub NewsWire • 11/16/2023 12:32:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2023 08:40:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/21/2023 08:30:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/15/2023 12:52:37 PM
- RENNOVA HEALTH, INC. ANNOUNCES THE EXPANSION OF SERVICES AT ITS BIG SOUTH FORK MEDICAL CENTER HOSPITAL, TO INCLUDE SWING BEDS • InvestorsHub NewsWire • 06/13/2023 04:56:47 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM